Evrópusambandið - íslenska - EMA (European Medicines Agency)

bayer animal health gmbh - imidacloprid, moxidectin - vörn gegn krabbameinslyfjum, skordýraeitum og repellents - dogs; cats; ferrets - dogsfor hundar þjáist af, eða í hættu, í bland sníkjudýra:meðferð og koma í veg fyrir fló árás (ctenocephalides sus),meðferð bíta lús (trichodectes canis),meðferð eyra ögn árás (otodectes cynotis), sarcoptic girl (af völdum sarcoptes scabiei var. canis), demodicosis (af völdum demodex canis),fyrirbyggja heartworm sjúkdómur (l3 og l4 lirfur dirofilaria immltís),meðferð streyma microfilariae (dirofilaria immltís),meðferð húð dirofilariosis (fullorðinn stigum dirofilaria repens)fyrirbyggja húð dirofilariosis (l3 lirfur dirofilaria repens),lækkun í gangi microfilariae (dirofilaria repens),fyrirbyggja angiostrongylosis (l4 lirfur og óþroskaður fullorðnir af angiostrongylus vasorum),meðferð angiostrongylus vasorum og crenosoma vulpis,fyrirbyggja spirocercosis (spirocerca lupi),meðferð eucoleus (syn. capillaria) boehmi (fullorðnir),meðferð auga worm thelazia callipaeda (fullorðnir),meðferð sýkingum með maga pöddurnar (l4 lirfur, óþroskaður fullorðnir og fullorðnir af toxocara canis, ancylostoma caninum og uncinaria stenocephala, fullorðna á toxascaris andreoletti og trichuris vulpis). varan er hægt að nota sem hluti af meðferðaráætlun fyrir flóaofnæmi húðbólgu (fad). catsfor kettir þjáist af, eða í hættu, í bland sníkjudýra:meðferð og koma í veg fyrir fló árás (ctenocephalides sus),meðferð eyra ögn árás (otodectes cynotis),meðferð notoedric girl (notoedres cati),meðferð lungworm eucoleus aerophilus (syn. capillaria aerophila) (fullorðnir),fyrirbyggja lungworm sjúkdómur (l3/l4 lirfur aelurostrongylus abstrusus),meðferð lungworm aelurostrongylus abstrusus (fullorðnir),meðferð auga worm thelazia callipaeda (fullorðnir),fyrirbyggja heartworm sjúkdómur (l3 og l4 lirfur dirofilaria immltís),meðferð sýkingum með maga pöddurnar (l4 lirfur, óþroskaður fullorðnir og fullorðnir af toxocara cati og ancylostoma tubaeforme). varan er hægt að nota sem hluti af meðferðaráætlun fyrir flóaofnæmi húðbólgu (fad). ferretsfor augu þjáist af, eða í hættu, í bland sníkjudýra:meðferð og koma í veg fyrir fló árás (ctenocephalides sus),fyrirbyggja heartworm sjúkdómur (l3 og l4 lirfur dirofilaria immltís).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

laboratorios hipra, s.a. - lifandi, bæklaða smitandi bursal sjúkdómur veira (ibdv), álag 1052 - Ónæmislyf fyrir aves, innlendum fugl, lifandi veiru bóluefni, fuglum smitandi bursal sjúkdómur veira (gumboro sjúkdómur) - chicken; embryonated chicken eggs - fyrir virk bólusetningar 1-daginn gamall neitt grill kjúklinga og embryonated neitt grill kjúklingur egg til að draga úr klínískum merki og sár bursa af fabricius af völdum mjög slæmt fugla smitandi bursal sjúkdómur veirusýkingu.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

orion corporation - tasipimidine sulfate - other hypnotics and sedatives - hundar - alleviation of situational anxiety and fear in dogs triggered by e. travel, noise, owner departure, veterinary visits.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

viatris limited - tadalafil - háþrýstingur, lungnabólga - Þvaglát - talmanco er ætlað í fullorðnir fyrir meðferð lungum slagæð háan blóðþrýsting (pah) flokkast sem hagnýtur ii og iii, til að bæta æfing getu. verkun hefur verið sýnd í sjálfvakta pah (ipah) og í pah í tengslum við krabbameinsvaldandi sjúkdóma.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

virbac s.a. - deslorelin asetat - hinsveiflur og heilahimnubólur og hliðstæður - dogs; ferrets - til að framkalla tímabundna ófrjósemi hjá heilbrigðum, heilum, kynþroska karlkyns hundum og frettum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - frumur tengd lifandi raðbrigða kalkúnduherpes veiru (rhvt / nd) sem tjá samrunaprótín newcastle sjúkdómsvirus d-26 lentogenic stofn - Ónæmislyf fyrir aves, lifandi veiru bóluefni - chicken; embryonated eggs - fyrir virk bólusetningar 18 daga gamall embryonated kjúklingur egg eða einn daginn gamall kjúklinga til að draga úr jörðu og klínískum merki af völdum newcastle sjúkdómur veira og til að draga úr jörðu klínískum merki og sár af völdum marek er sjúkdómur veira með svipgerð "slæmt".

Evrópusambandið - íslenska - EMA (European Medicines Agency)

alexion europe sas - eculizumab - blóðrauði, ofsakláði - Ónæmisbælandi lyf - soliris er ætlað í fullorðna og börn fyrir meðferð:paroxysmal nóttu haemoglobinuria (pnh). sönnunargögn klínískum gagn er sýnt í sjúklinga með haemolysis með klínískum einkenni(s) marks um hár sjúkdómur starfsemi, óháð blóðgjöf sögu (sjá kafla 5. Óhefðbundin blóðlýsu uremic (ahus). soliris er ætlað í fullorðnir fyrir meðferð:svarar almenn vöðvaslensfár (gmg) í sjúklingum sem eru anti-asetýlkólíns viðtaka (achr) mótefni-jákvæð (sjá kafla 5. neuromyelitis optica svið röskun (nmosd) í sjúklingum sem eru anti-aquaporin-4 (aqp4) mótefni-jákvæð við köstum auðvitað sjúkdómsins.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

merck sharp and dohme b.v - posakónazól - candidiasis; mycoses; coccidioidomycosis; aspergillosis - sveppalyf fyrir almenn nota - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 og 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 og 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. svara ekki meðferð er skilgreint eins og framgangi sýkingu eða bilun til að bæta eftir að minnsta kosti 7 daga áður en lækninga skammta af árangri mikla meðferð. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 og 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 og 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 og 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. svara ekki meðferð er skilgreint eins og framgangi sýkingu eða bilun til að bæta eftir að minnsta kosti 7 daga áður en lækninga skammta af árangri mikla meðferð. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 og 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 og 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. svara ekki meðferð er skilgreint eins og framgangi sýkingu eða bilun til að bæta eftir að minnsta kosti 7 daga áður en lækninga skammta af árangri mikla meðferð. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor. svara ekki meðferð er skilgreint eins og framgangi sýkingu eða bilun til að bæta eftir að minnsta kosti 7 daga áður en lækninga skammta af árangri mikla meðferð. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

takeda pharma a/s - azilsartan medoxomil - háþrýstingur - lyf sem hafa áhrif á renín-angíótensín kerfið - ipreziv er ætlað til meðferðar við nauðsynlegum háþrýstingi hjá fullorðnum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

roche registration gmbh - baloxavir marboxil - inflúensu, manna - veirueyðandi lyf til almennrar notkunar - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.